Myelin oligodendrocyte glycoprotein (MOG) antibody-associated syndromes are now considered a distinct and new entity in the field of CNS inflammatory demyelinating disorders, different from multiple sclerosis and aquaporin4-IgG-positive neuromyelitis optica.1 MOG antibody-associated syndromes are associated with a young age at onset and are common in children with acquired demyelinating syndrome.2 Although recent large-scale studies have brought new insight to the field, many open questions still remain, including their prevalence, the entire clinical spectrum, prognostic and predictive factors, and treatment strategies.